A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes

Yehoshua Gozes, Douglas E. Brenneman*, Mati Fridkin, Richard Asofsky, Illana Gozes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Vasoactive intestinal peptide (VIP) is a neuropeptide which also interacts with cells of the immune system. The paucity of specific VIP receptor antagonists has hampered studies of possible receptor heterogeneity and of VIP function. To aid in achieving these goals, a new VIP antagonist, a hybrid between neurotensin and VIP, has been synthesized. This peptide interacted with VIP receptors on spinal cord cells with an affinity 10-fold greater than VIP itself. In contrast, 1000-fold higher concentrations of the antagonist were required to displace labeled VIP from its receptor on lymphoid cells as compared to VIP itself, suggesting VIP receptor heterogeneity between immune and spinal cord cells.

Original languageEnglish
Pages (from-to)319-321
Number of pages3
JournalBrain Research
Issue number1-2
StatePublished - 1 Feb 1991


  • Lymphocyte
  • Spinal cord cell culture
  • Vasoactive intestinal peptide
  • Vasoactive intestinal peptide receptor antagonist
  • Vasoactive intestinal receptor


Dive into the research topics of 'A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes'. Together they form a unique fingerprint.

Cite this